ONCONasdaqPharmaceutical PreparationsFiscal year ends December 31
Onconetix, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.43−0.05 (-10.13%)
Close on Oct 19, 2026
- Market cap
- $965.06K
- P/E (TTM)
- –
- Dividend yield
- –
Onconetix statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Onconetix | Industry median |
|---|---|---|
| Market Cap | $1.70M | $197.05M |
| Enterprise Value | -$4.24M | $106.56M |
| PS Ratio | 2.63 | 3.93 |
| PB Ratio | 0.13 | 2.14 |
| P/TBV Ratio | 0.44 | 2.46 |
Enterprise value
| Measure | Onconetix | Industry median |
|---|---|---|
| EV / Sales | -6.57 | 2.69 |
Income (trailing twelve months)
| Measure | Onconetix | Industry median |
|---|---|---|
| Revenue | $645.82K | $57.94M |
| Gross Profit | $519.23K | $90.47M |
| Operating Income | -$16.31M | -$21.44M |
| Pretax Income | -$10.20M | -$14.45M |
| Net Income | -$10.20M | -$22.46M |
| EBITDA | -$16.29M | -$16.91M |
Margins
| Measure | Onconetix | Industry median |
|---|---|---|
| Gross Margin | 80.4% | 52.3% |
| Operating Margin | -2525.0% | -44.5% |
| Pretax Margin | -1578.7% | -13.0% |
| Profit Margin | -1578.8% | -39.2% |
| EBITDA Margin | -2522.7% | -31.3% |
Returns
| Measure | Onconetix | Industry median |
|---|---|---|
| Return on Equity (ROE) | -105.2% | -53.1% |
| Return on Assets (ROA) | -57.4% | -41.0% |
| Return on Invested Capital (ROIC) | -195.9% | -32.0% |
| Return on Capital Employed (ROCE) | -121.0% | -37.8% |
Growth
| Measure | Onconetix | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -51.3% | 6.01% |
Balance sheet
| Measure | Onconetix | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $5.94M | $62.42M |
| Net Cash (Debt) | $5.94M | $15.68M |
| Net Cash Per Share | $1.50 | $0.65 |
| Equity (Book Value) | $13.47M | $48.79M |
| Book Value Per Share | $3.41 | $1.36 |
| Tangible Book Value | $3.85M | $23.06M |
| Working Capital | $3.57M | $75.77M |
Financial position
| Measure | Onconetix | Industry median |
|---|---|---|
| Current Ratio | 2.21 | 3.30 |
| Quick Ratio | 2.02 | 2.39 |
| Interest Coverage | -52.44 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Onconetix | Industry median |
|---|---|---|
| Operating Cash Flow | -$10.31M | -$12.35M |
Efficiency
| Measure | Onconetix | Industry median |
|---|---|---|
| Asset Turnover | 0.04 | 0.38 |
| Inventory Turnover | 0.70 | 2.67 |
| Revenue Per Employee | $53.82K | $398.96K |
| Profits Per Employee | -$849.68K | -$732.08K |
| Employee Count | 12 | 73 |
Dividends and yields
| Measure | Onconetix | Industry median |
|---|---|---|
| Earnings Yield | -600.0% | -21.2% |
Shares
| Measure | Onconetix | Industry median |
|---|---|---|
| Shares Outstanding | 3,949,110 | 59,128,900 |
| Shares Change (QoQ) | 37.7% | 0.54% |
| Float | 2,356,730 | 48,744,500 |
| Shares Held by Insiders | 40.3% | 11.8% |
| Shares Held by Institutions | 1.66% | 59.4% |
Scores
| Measure | Onconetix | Industry median |
|---|---|---|
| Altman Z-Score | -14.42 | 0.10 |
| Piotroski F-Score | 6 | 4 |
| Beneish M-Score | 27.95 | -2.62 |
Calculated by StockData from Onconetix's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.